Top

Published in:

Open Access 01-02-2008 | Original Article

Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas

Authors: Hua-chuan Zheng, Hiroyuki Takahashi, Xiao-han Li, Takuo Hara, Shinji Masuda, Yi-fu Guan, Yasuo Takano

Published in: Virchows Archiv | Issue 2/2008

Abstract

Parafibromin is a protein encoded by the hyperparathyroidism 2 oncosuppressor gene and its downregulated expression is involved in pathogenesis of parathyroid carcinomas. To clarify the roles of parafibromin expression in tumourigenesis and progression of gastric carcinomas, it was examined by immunohistochemistry (IHC) on tissue microarray containing gastric carcinomas (n = 508), adenomas (n = 45) and gastritis (n = 49) with a comparison of its expression with clinicopathological parametres of carcinomas. Gastric carcinoma cell lines (MKN28, AGS, MKN45, KATO-III and HGC-27) were studied for parafibromin expression by IHC and western blot. Parafibromin expression was localised in the nucleus of gastric epithelial cells, adenoma, carcinoma cells and cell lines. Its expression was gradually decreased from gastritis to gastric carcinoma, through gastric adenomas (p < 0.05) and inversely correlated with tumour size, depth of invasion, lymphatic invasion, lymph node metastasis and Union Internationale Contre le Cancer (UICC) staging (p < 0.05) but not with sex or venous invasion (p > 0.05). Parafibromin was strongly expressed in older carcinoma patients compared with younger ones (p < 0.05). There was stronger positivity of parafibromin in intestinal-type than diffuse-type carcinomas (p < 0.05). Univariate analysis indicated cumulative survival rate of patients with positive parafibromin expression to be higher than without its expression (p < 0.05). Multivariate analysis showed that age, tumour size, depth of invasion, lymphatic invasion, lymph node metastasis, UICC staging and Lauren’s classification but not sex, venous invasion or parafibromin expression were independent prognostic factors for carcinomas(p < 0.05). Downregulated parafibromin expression possibly contributed to pathogenesis, growth, invasion and metastasis of gastric carcinomas. It was considered as a promising marker to indicate the aggressive behaviours and prognosis of gastric carcinomas.

Aldred MJ, Talacko AA, Savarirayan R, Murdolo V, Mills AE, Radden BG, Alimov A, Villablanca A, Larsson C (2006) Dental findings in a family with hyperparathyroidism–jaw tumour syndrome and a novel HRPT2 gene mutation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101:212–218PubMedCrossRef

Bradley KJ, Bowl MR, Williams SE, Ahmad BN, Partridge CJ, Patmanidi AL, Kennedy AM, Loh NY, Thakker RV (2007) Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal. Oncogene 26:1213–1221PubMedCrossRef

Bradley KJ, Cavaco BM, Bowl MR, Harding B, Young A, Thakker RV (2005) Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism. J Med Genet 42:e51PubMedCrossRef

Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Hoog A, Heath H, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C, Hobbs MR (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumour syndrome. Nat Genet 32:676–680PubMedCrossRef

Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, Howell VM, Marsh DJ (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism−jaw tumour (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30:1140–1149PubMed

Hahn MA, Marsh DJ (2005) Identification of a functional bipartite nuclear localization signal in the tumour suppressor parafibromin. Oncogene 24:6241–6248PubMedCrossRef

Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H, Teh BT (2003) HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40:657–663PubMedCrossRef

Juhlin C, Larsson C, Yakoleva T, Leibiger I, Leibiger B, Alimov A, Weber G, Hoog A, Villablanca A (2006) Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr Relat Cancer 13:509–523PubMedCrossRef

Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1–9PubMedCrossRef

10.

Krogan NJ, Dover J, Wood A, Schneider J, Heidt J, Boateng MA, Dean K, Ryan OW, Golshani A, Johnston M, Greenblatt JF, Shilatifard A (2003) The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: linking transcriptional elongation to histone methylation. Mol Cell 11:721–729PubMedCrossRef

11.

Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y (2004) Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol 17:1141–1149PubMedCrossRef

12.

Kurokawa T, Fuchigami A (1967) Gastric carcinoma in its early stages. Naika 20:824–829PubMed

13.

Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49PubMed

14.

Lin L, Czapiga M, Nini L, Zhang JH, Simonds WF (2007) Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism–jaw tumor syndrome enhances its proapoptotic function. Mol Cancer Res 5:183–193PubMedCrossRef

15.

Mosimann C, Hausmann G, Basler K (2006) Parafibromin/hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell 125:327–341PubMedCrossRef

16.

Pimenta FJ, Gontijo Silveira LF, Tavares GC, Silva AC, Perdigao PF, Castro WH, Gomez MV, Teh BT, De Marco L, Gomez RS (2006) HRPT2 gene alterations in ossifying fibroma of the jaws. Oral Oncol 42:735–739PubMedCrossRef

17.

Porzionato A, Macchi V, Barzon L, Masi G, Iacobone M, Parenti A, Palu G, De Caro R (2006) Immunohistochemical assessment of parafibromin in mouse and human tissues. J Anat 209:817–827PubMedCrossRef

18.

Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T, Resau JH, Meyerson M (2005) The parafibromin tumour suppressor protein is part of a human Paf1 complex. Mol Cell Biol 25:612–620PubMedCrossRef

19.

Selvarajan S, Sii LH, Lee A, Yip G, Bay BH, Tan MH, Teh BT, Tan PH (2007) Parafibromin expression in breast cancer: a novel marker for prognostication? J Clin Pathol (in press)

20.

Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722–1729PubMedCrossRef

21.

Sobin LH, Wittekind CH (2002) TNM classification of malignant tumours, 6th edn. Wiley, Hoboken

22.

Tan MH, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, Zhao P, Tretiakova MS, Korpi-Hyovalti E, Burgess JR, Soo KC, Cheah WK, Cao B, Resau J, Morreau H, Teh BT (2004) Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 10:6629–6637PubMedCrossRef

23.

Wang PF, Tan MH, Zhang C, Morreau H, Teh BT (2005) HRPT2, a tumour suppressor gene for hyperparathyroidism-jaw tumour syndrome. Horm Metab Res 37:380–383PubMedCrossRef

24.

Wood A, Krogan NJ, Dover J, Schneider J, Heidt J, Boateng MA, Dean K, Golshani A, Zhang Y, Greenblatt JF, Johnston M, Shilatifard A (2003) Bre1, an E3 ubiquitin ligase required for recruitment and substrate selection of Rad6 at a promoter. Mol Cell 11:267–274PubMedCrossRef

25.

Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ, Simonds WF (2005) Parafibromin, product of the hyperparathyroidism–jaw tumour syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 24:1272–1276PubMedCrossRef

26.

Yang GY, Zhang YC, Liu XD, Wu YQ, Li MS, Gong CY, Guan BW, Mi DH, Liu S (1992) Geographic pathology on the precursors of stomach cancer. J Environ Pathol Toxicol Oncol 11:339–344PubMed

27.

Yart A, Gstaiger M, Wirbelauer C, Pecnik M, Anastasiou D, Hess D, Krek W (2005) The HRPT2 tumour suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol 25:5052–5060PubMedCrossRef

28.

Zhang C, Kong D, Tan MH, Pappas DL, Wang PF, Chen J, Farber L, Zhang N, Koo HM, Weinreich M, Williams BO, Teh BT (2006) Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochem Biophys Res Commun 350:17–24PubMedCrossRef

29.

Zheng HC, Sun JM, Li XH, Yang XF, Zhang YC, Xin Y (2003) Role of PTEN and MMP-7 expression in growth, invasion, metastasis and angiogenesis of gastric carcinoma. Pathol Int 53:659–666PubMedCrossRef

30.

Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, Tsuneyama K, Takano Y Low expression of FHIT and PTEN correlates with malignancy of gastric carcinomas. Appl Immunohistochem Mol Morphol (in press)

31.

Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, Tsuneyama K, Takano Y (2007) Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol 60:273–277PubMedCrossRef

32.

Zheng HC, Takahashi H, Murai Y, Cui ZG, Nomoto K, Miwa S, Tsuneyama K, Takano Y (2006) Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer 95:1371–1378PubMedCrossRef

33.

Zheng H, Takahashi H, Nakajima T, Murai Y, Cui Z, Nomoto K, Tsuneyama K, Takano Y (2006) MUC6 down-regulation correlates with gastric carcinoma progression and a poor prognosis: an immunohistochemical study with tissue microarrays. J Cancer Res Clin Oncol 132:817–823PubMedCrossRef

34.

Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, Fujii C, Nomoto K, Mukaida N, Takano Y (2007) Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol (in press)

Title: Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas
Authors: Hua-chuan Zheng
Hiroyuki Takahashi
Xiao-han Li
Takuo Hara
Shinji Masuda
Yi-fu Guan
Yasuo Takano
Publication date: 01-02-2008
Publisher: Springer-Verlag
Published in: Virchows Archiv / Issue 2/2008
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-007-0551-z

At a glance: The STEP trials

Springer Medicine

Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Systemic Erdheim–Chester disease

Mucosal colonization of gastric endocrine tumors mimicking mixed neoplasms

Peritumoural, but not intratumoural, lymphatic vessel density and invasion correlate with colorectal carcinoma poor-outcome markers

Primary clear cell meningioma of the orbit mimicking a metastatic carcinoma: usefulness of immunohistochemistry and cytogenetic analysis

Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas

Proteomic identification of heat shock protein 27 as a differentiation and prognostic marker in neuroblastoma but not in Ewing’s sarcoma